膀胱癌circRNAs介导的ceRNA网络及预后评估模型的构建

doi:10.6040/j.issn.1671-7554.0.2021.0231

摘要/Abstract

摘要： 目的探究膀胱癌中差异性表达的环状RNAs(circRNAs),并构建circRNAs介导的ceRNA网络及预后评估模型。方法下载并分析基因表达数据库(GEO)和癌症基因组图谱(TCGA)中膀胱癌RNA测序数据,以|log2 fold change(log2FC)|>1、P-value<0.05为纳入标准,筛选RNA差异表达谱。整合TCGA膀胱癌RNA差异分析数据及CircInteractome等公共数据库数据,构建circRNA-miRNA-mRNA ceRNA网络,通过GEO与TCGA对网络中mRNAs进行功能富集分析。利用String数据库挖掘ceRNA网络分子的相互作用关系。采用Cox回归分析筛选预后相关mRNAs,并构建膀胱癌预后风险评估模型;利用“time ROC”软件包绘制ROC曲线,对模型效能进行评估。结果通过2个GEO数据集的差异分析,共筛选到4个circRNAs,分别是hsa_circ_0102787、hsa_circ_0103114、hsa_circ_0102402与hsa_circ_0104387。通过公共数据库及TCGA差异分析,构建了由circRNAs介导的ceRNA网络,包含4个circRNAs、23个miRNAs和86个mRNAs;功能富集分析显示该网络mRNAs涉及多个与肿瘤调控相关的生物学过程;网络中mRNAs存在相互作用关系,生存分析显示6个mRNAs与膀胱癌预后相关。以“风险评分=(-0.356 9)×ABRACL+(-0.264 4)×MAP3K8”构建膀胱癌预后风险评估模型,Kaplan-Meier曲线提示高评分组预后差(P<0.001),模型5年总体生存率的AUC=0.744。结论发掘4个膀胱癌中表达失调的circRNAs,构建了膀胱癌相关circRNA-miRNA-mRNA网络及预后评估模型,为揭示膀胱癌发生发展的分子机制及寻找新的诊断、预后标志物奠定了理论基础。

关键词: 膀胱癌, circRNAs, ceRNA, 预后, Cox风险评估模型

Abstract: Objective To identify the differentially expressed circular RNAs(circRNAs)and construct a circRNAs-mediated ceRNA network and a prognostic assessment model. Methods Data were downloaded from Gene Expression Omnibus(GEO)and The Cancer Genome Atlas(TCGA)database. Differential expressed analysis was performed to explore the differentially expressed RNAs in bladder cancer tissues with the standard of |log2 fold change(log2FC)|>1, P<0.05. Based on multiple detabases, such as TCGA and CircInteractome, the circRNA-miRNA-mRNA ceRNA network was constructed, and functional enrichment analysis of mRNAs was conducted. Subsequently, the relationship of mRNAs in ceRNA network was analyzed through the String database. The mRNAs related to prognosis were screened with univariate Cox regression model, and a prognostic assessment model was constructed. A ROC curve was drawn with “time ROC” package to evaluate the effectiveness of the model. Results Differential expressed analysis screened out 4 circRNAs, including hsa_circ_0102787, hsa_circ_0103114, hsa_circ_0102402 and hsa_circ_0104387. A ceRNA network was constructed, which contained 4 circRNAs, 23 miRNAs and 86 mRNAs. Functional enrichment analysis showed those mRNAs participated in several cancer-related pathways. The interaction between mRNAs in the ceRNA network was visualized by PPI network. Survival analysis revealed that 6 mRNAs were related to the prognosis of bladder cancer. Then, a prognostic assessment model was constructed based on “the risk score=(-0.356 9)×ABRACL+(-0.264 4)×MAP3K8.” Kaplan Meier analysis showed patients with high risks had a poor prognosis(P<0.001), and the AUC of the five-year overall survival rate was 0.744. Conclusion This study identififed 4 differentially expressed circRNAs, and constructed a circRNA-miRNA-mRNA network and a prognostic assessment model, which provides a new insight for the exploration of the occurrence and development of bladder cancer.

Key words: Bladder cancer, circRNAs, ceRNA, Prognosis, Cox regression model

中图分类号:

R737.14

米琦,史爽,李娟,李培龙,杜鲁涛,王传新. 膀胱癌circRNAs介导的ceRNA网络及预后评估模型的构建[J]. 山东大学学报 (医学版), 2021, 59(6): 94-102.

MI Qi, SHI Shuang, LI Juan, LI Peilong, DU Lutao, WANG Chuanxin. Construction of circRNA-mediated ceRNA network and prognostic assessment model for bladder cancer[J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 94-102.

参考文献

[1] Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends [J]. Eur Urol, 2017, 71(1): 96-108.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[3] Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer [J]. Cell, 2017, 171(3): 540-556.
[4] Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer [J]. Lancet, 2016, 388(10061): 2796-2810.
[5] Witjes JA, Lebret T, Comperat EM, et al. Updated 2016 EAU Guidelines on muscle-invasive and metastatic bladder cancer [J]. Eur Urol, 2017, 71(3): 462-475.
[6] Dreicer R. Chemotherapy for advanced urothelial cancer: end of the beginning? [J]. Lancet Oncol, 2017, 18(5): 567-569.
[7] Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus calmette-guerin [J]. Eur Urol, 2016, 69(1): 60-69.
[8] Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs [J]. Nat Biotechnol, 2014, 32(5): 453-461.
[9] Liu YC, Li JR, Sun CH, et al. CircNet: a database of circular RNAs derived from transcriptome sequencing data [J]. Nucleic Acids Res, 2016, 44(D1): D209-215.
[10] Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency [J]. Nature, 2013, 495(7441): 333-338.
[11] Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition [J]. Nature, 2014, 505(7483): 344-352.
[12] Su Y, Feng W, Shi J, et al. Correction to: circRIP2 accelerates bladder cancer progression via miR-1305/Tgf-β2/smad3 pathway [J]. Mol Cancer, 2021, 20(1): 1. doi: 10.1186/s12943-019-1129-5.
[13] Su H, Tao T, Yang Z, et al. Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression [J]. Mol Cancer, 2019, 18(1): 27. doi: 10.1186/s12943-019-0951-0.
[14] Meng S, Zhou H, Feng Z, et al. CircRNA: functions and properties of a novel potential biomarker for cancer [J]. Mol Cancer, 2017, 16(1): 94. doi: 10.1186/s12943-017-0663-2.
[15] Wang Z, Jensen MA, Zenklusen JC. A practical guide to the cancer genome atlas(TCGA)[J]. Methods in molecular biology(Clifton, NJ), 2016, 1418: 111-141. doi: 10.1007/978-1-4939-3578-9_6.
[16] Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies [J]. Nucleic acids research, 2015, 43(7): e47. doi: 10.1093/nar/gkv007.
[17] Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data [J]. Bioinformatics, 2010, 26(1): 139-140.
[18] Dudekula DB, Panda AC, Grammatikakis I, et al. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs [J]. RNA Biol, 2016, 13(1): 34-42.
[19] Jiang J, Bi Y, Liu XP, et al. To construct a ceRNA regulatory network as prognostic biomarkers for bladder cancer [J]. J Cell Mol Med, 2020, 24(9): 5375-5386.
[20] Otasek D, Morris JH, Boucas J, et al. Cytoscape Automation: empowering workflow-based network analysis [J]. Genome Biol, 2019, 20(1): 185. doi: 10.1186/s13059-019-1758-4.
[21] Kanehisa M, Furumichi M, Tanabe M, et al. KEGG: new perspectives on genomes, pathways, diseases and drugs [J]. Nucleic Acids Res, 2017, 45(D1): D353-D361.
[22] Gene OC. Gene ontology consortium: going forward [J]. Nucleic Acids Res, 2015, 43(Database issue): D1049-1056.
[23] Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets [J]. Nucleic Acids Res, 2019, 47(D1): D607-D613.
[24] Weng W, Wei Q, Toden S, et al. Circular RNA ciRS-7-A promising prognostic biomarker and a potential therapeutic target in colorectal cancer [J]. Clin Cancer Res, 2017, 23(14): 3918-3928.
[25] Cheng Z, Yu C, Cui S, et al. circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1 [J]. Nat Commun, 2019, 10(1): 3200. doi: 10.1038/s41467-019-11162-4.
[26] Zeng Z, Zhou W, Duan L, et al. Circular RNA circ-VANGL1 as a competing endogenous RNA contributes to bladder cancer progression by regulating miR-605-3p/VANGL1 pathway[J]. J Cell Physiol, 2019, 234(4): 3887-3896.
[27] 史爽, 李娟, 米琦, 等. 胃癌miRNAs预后风险评分模型的构建与应用[J]. 山东大学学报(医学版), 2020, 58(7): 47-52. SHI Shuang, LI Juan, MI Qi, et al. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer [J]. Journal of Shandong University(Health Sciences), 2020, 58(7): 47-52.
[28] Chen Y, Xu T, Xie F, et al. Evaluating the biological functions of the prognostic genes identified by the Pathology Atlas in bladder cancer [J]. Oncol Rep, 2021, 45(1): 191-201.
[29] Vougioukalaki M, Kanellis DC, Gkouskou K, et al. Tpl2 kinase signal transduction in inflammation and cancer[J]. Cancer Letters, 2011, 304(2): 80-89.

相关文章 15

[1]	李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[2]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[3]	王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[4]	贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[5]	杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[6]	杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[7]	刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[8]	陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71.
[9]	郭姝画,樊扬,田风,王传新,杜鲁涛,李培龙,郭兴,徐硕. 微原纤维相关蛋白3在调控胶质瘤干细胞间充质表型转化中的作用[J]. 山东大学学报 (医学版), 2024, 62(6): 9-16.
[10]	杨瀚,张宗亮,赵凯,尹心宝,朱冠群,张玉莲,王振林,闫学川,王科. 腹腔镜下膀胱全切和原位新膀胱术治疗肾移植术后膀胱癌1例[J]. 山东大学学报 (医学版), 2024, 62(6): 122-124.
[11]	魏闫若雪,李梓绮,刘春铖,刘晓晗,赵然,刘玉昆. 结直肠癌中SP1的瘤内异质性表达及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(5): 89-94.
[12]	刘春铖,刘晓晗,魏闫若雪,李梓绮,刘玉昆,赵然. 结直肠癌中含溴结构域蛋白9的亚细胞定位模式及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(4): 24-30.
[13]	杨雪彦,吴寅平,吕丽,赵泽华,马行宇,李凤彩,王凯,范玉琛. 单核细胞与淋巴细胞比值动态变化对慢加急性乙型肝炎肝衰竭预后的诊断价值[J]. 山东大学学报 (医学版), 2024, 62(3): 61-69.
[14]	刁玉洁,林琳,李文瑄,王洲洋,江蓓,胡迎迎,刘广义. NPR预测ANCA相关血管炎不良肾脏预后及其协同多因素优化模型[J]. 山东大学学报 (医学版), 2024, 62(2): 60-68.
[15]	宋兆录,董正璇,彭传真,黄彩娜,胡克清,黄永胜,阎磊. 肾透明细胞癌中预后相关RNA编辑位点的筛选[J]. 山东大学学报 (医学版), 2023, 61(9): 69-78.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed